TickerWorth Value any ticker →

Most undervalued Healthcare stocks — per our blended fair value

Healthcare names ranked by how far the market price sits below our base-case DCF fair value. Educational estimate, not a recommendation.

SOLVSolventum Corporation+168.0% to fair valueDVADaVita Inc.+159.6% to fair valueHCAHCA Healthcare, Inc.+158.9% to fair valueBMYBristol-Myers Squibb Company+110.5% to fair value4578.TOtsuka Holdings Co., Ltd.+103.7% to fair valueFRE.DEFresenius SE & Co. KGaA+99.1% to fair valueZTSZoetis Inc.+93.2% to fair valueCCLDCareCloud, Inc.+92.8% to fair valueGEHCGE HealthCare Technologies Inc.+92.2% to fair valueNVONovo Nordisk A/S+76.5% to fair valueZBHZimmer Biomet Holdings, Inc.+76.4% to fair valueELVElevance Health, Inc.+69.6% to fair valueAZN.LAstraZeneca PLC+62.2% to fair valueCORCencora, Inc.+61.9% to fair valueINCYIncyte Corporation+51.3% to fair valueHUMHumana Inc.+48.1% to fair valueBSXBoston Scientific Corporation+46.2% to fair valueALGNAlign Technology, Inc.+44.7% to fair valueMDTMedtronic plc+41.5% to fair valueAUROPHARMA.NSAurobindo Pharma Limited+40.9% to fair valueMRK.DEMerck KGaA+40.0% to fair valueHSICHenry Schein, Inc.+37.7% to fair valueAZNAstraZeneca PLC+37.0% to fair valueDGXQuest Diagnostics Incorporated+36.3% to fair valueLHLabcorp Holdings Inc.+35.5% to fair value4502.TTakeda Pharmaceutical Company Limited+35.1% to fair valueMCKMcKesson Corporation+31.5% to fair valueSTESTERIS plc+30.5% to fair valueBIIBBiogen Inc.+28.7% to fair valuePODDInsulet Corporation+25.2% to fair valueCHEChemed Corporation+24.2% to fair valueGLENMARK.NSGlenmark Pharmaceuticals Limited+21.5% to fair valueCAHCardinal Health, Inc.+21.0% to fair valueBDXBecton, Dickinson and Company+20.4% to fair valueCVSCVS Health Corporation+15.7% to fair value

Related screens

By market: All · US · Indian · UK · Canadian · German · French · Japanese · Hong Kong · Australian · Brazilian · Dutch · Swiss · Italian · Spanish · Swedish

By sector: Technology · Industrials · Consumer · Energy · Communication

Educational DCF estimates from public filings and market data — not investment advice.